KED / Vesugen: defined peptide and microcirculation claims — US7851449B2
Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorovich Malinin, Galina Anatolievna Ryzhak · 2010 · US7851449B2 · patent family 37999085
Published 2010-12-14.
Reported patent results
Reported findings
The patent reports improved cuff-test resistance and changes in coagulation measures after ten days.
Purpura-senilis patent comparison in 23 people aged 70–82: 12 receiving KED and 11 saline; the text states random division.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cuff test | Treated group III–IV → II; control III–IV → III–IV | Ordinal capillary-resistance measure · 10-day course · p<0.05 before/after in treated group |
| Recalcification time | 164.2 ± 2.4 with KED versus 147.3 ± 4.2 control | Healthy comparison value 178.0 ± 14.0; not a clinical vascular event · p<0.05 versus control |
| Activated partial thromboplastin time | 58.9 ± 0.7 versus 48.0 ± 1.3 seconds; healthy reference 32.3 ± 2.1 | The treated value moves further from this reference; not every measure is normalized |
Very small patent comparison, with masking and allocation concealment unverified. Laboratory changes do not establish clinical prevention, and the source’s normalization language overstates at least one displayed measure.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The granted claims explicitly identify H-Lys-Glu-Asp-OH and compositions or methods involving microcirculation disorders.
Defined KED is not automatically identical to a branded multicomponent capsule or vascular tissue extract.
- Publication
- US7851449B2 ↗ · 2010-12-14
- Earliest priority / filing
- 2006-05-23 / 2006-12-04
- Original applicant / assignee
- SIA Peptides OOO
- Indexed status
- Active - Reinstated · checked 2026-11-06
- Patent family
- 37999085 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide, pharmaceutical composition, and a method of treating microcirculation disorders
Inventors: Vladimir Khatskelevich Khavinson; Evgeny Iosifovich Grigoriev; Vladimir Victorovich Malinin; Galina Anatolievna Ryzhak.
US7851449B2 · EP2024387B1 · KR20090009867A · ATE446309T1 · DE602006009976D1 · DK2024387T3 · EA010158B1 · IL194500A · RU2295970C1 · UA91137C2 · WO2007136294A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Defined KED is not automatically identical to a branded multicomponent capsule or vascular tissue extract.
- Very small patent comparison, with masking and allocation concealment unverified. Laboratory changes do not establish clinical prevention, and the source’s normalization language overstates at least one displayed measure.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-37999085. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorovich Malinin, Galina Anatolievna Ryzhak. KED / Vesugen: defined peptide and microcirculation claims — US7851449B2 US7851449B2 · patent family 37999085 2010.
Molekul research summary: https://molekul.io/research/patent-us7851449b2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Vesugen
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
KED
A tripeptide research entry connected to experimental neurodegeneration work. No human benefit is inferred from mouse-model findings.